Corcept Therapeutics (CORT) vs. Its Rivals Head-To-Head Comparison

Corcept Therapeutics (NASDAQ:CORT) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Corcept Therapeutics to related companies based on the strength of its institutional ownership, valuation, dividends, profitability, risk, earnings and analyst recommendations.

Valuation and Earnings

This table compares Corcept Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	$99.65 million	57.30
Corcept Therapeutics Competitors	$3.54 billion	$3.17 billion	554.50

Corcept Therapeutics’ competitors have higher revenue and earnings than Corcept Therapeutics. Corcept Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Corcept Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	2	5	0	2.50
Corcept Therapeutics Competitors	7792	13886	25777	1037	2.41

Corcept Therapeutics presently has a consensus price target of $139.50, suggesting a potential upside of 91.70%. As a group, “Pharmaceuticals” companies have a potential upside of 25.45%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Corcept Therapeutics is more favorable than its competitors.

Volatility & Risk

Corcept Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Corcept Therapeutics’ competitors have a beta of -3.70, meaning that their average share price is 470% less volatile than the S&P 500.

Institutional and Insider Ownership

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Corcept Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Corcept Therapeutics Competitors	-2,372.59%	-220.82%	-15.99%

Summary

Corcept Therapeutics beats its competitors on 9 of the 13 factors compared.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.